Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
October 16 2017 - 9:00AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced the appointment of Kamalam (Kam) Unninayar as Chief
Financial Officer.
Kam joins Tetraphase with a track record of over two decades of
financial leadership in the life sciences and consumer goods
industries. Most recently, Kam spent over 11 years overseeing
finance organizations at Thermo Fisher Scientific, a global leader
in serving science. Across her multiple roles at Thermo Fisher, she
led financial operations, corporate financial planning and
analysis, and finance for business strategy. During her tenure
there, Kam led finance for the customer channels group, the
chemical analysis division, and businesses with revenues that
ranged from $200 million to $4 billion.
"We are delighted to welcome Kam at this exciting time for the
Company," said Guy Macdonald, President and Chief Executive
Officer of Tetraphase. "Kam’s strong financial leadership
experience and strategic business insight will be a valuable
addition to the executive team at Tetraphase, particularly as we
continue to build the infrastructure to support the
commercialization of eravacycline, our lead antibiotic
candidate.”
“I am thrilled to join Tetraphase, a company committed to
bringing innovative medicines to patients to address the growing
public health crisis of antibiotic resistance,” said Ms. Unninayar.
“At this pivotal time for the company, I look forward to working
with the team as it prepares to deliver on this mission.”
Kam holds a master of science in administration from Wichita
State University, as well as a master of finance & control and
bachelor of commerce from the University of Delhi, India.
Inducement Equity AwardsAdditionally,
Tetraphase's Compensation Committee of the Board of Directors
approved, pursuant to Rule 5635(c)(4) of the Nasdaq Global Select
Market, options to Ms. Unninayar to purchase 190,000 shares of
Tetraphase's common stock. The option was granted as an inducement
equity award outside Tetraphase's 2013 Stock Incentive Plan and was
made as an inducement material to Ms. Unninayar’s acceptance of
employment with Tetraphase. The option grant has an exercise price
equal to the closing price of Tetraphase's common stock on November
15, 2017. The option has a ten-year term and vests over four years,
with 25% of the original number of shares vesting on November 15,
2018 and an additional 6.25% of the original number of shares
vesting at the end of each successive quarter thereafter, subject
to Ms. Unninayar’s continued service with Tetraphase through the
applicable vesting dates.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical development, and TP-271 and TP-6076, which
are in phase 1 clinical trials. Please visit www.tphase.com for
more company information.
Forward-Looking StatementsAny statements in
this press release about our future expectations, plans and
prospects, including statements regarding our strategy, future
operations, prospects, plans and objectives, and other statements
containing the words "anticipates," "believes," "expects," "plans,"
"will" and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: whether the results of the Company's
development efforts will warrant regulatory submission and whether
any such submissions will receive approval from the United States
Food and Drug Administration or equivalent foreign regulatory
agencies; whether, if any clinical candidate obtains approval, it
will be successfully distributed and marketed; and other factors
discussed in the "Risk Factors" section of our quarterly report on
Form 10-Q, filed with the Securities and Exchange Commission on
August 2, 2017. In addition, the forward-looking statements
included in this press release represent our views as of October
16, 2017. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to
update these forward-looking statements at some point in the
future, we specifically disclaim any obligation to do so.
Investor Contacts:Tetraphase
PharmaceuticalsTeri Dahlman617-600-7040tdahlman@tphase.com
Argot PartnersMaeve
Conneighton206.899.4940maeve@argotpartners.com
Media Contact:Sam Brown Inc.Mike
Beyer312-961-2502Mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Sep 2023 to Sep 2024